title: Vitiligo associated with tolcapone and levodopa in a patient with Parkinson's disease.
authors.forename: M
authors.initials: M
authors.lastname: Sabaté
authors.forename: A
authors.initials: A
authors.lastname: Bosch
authors.forename: C
authors.initials: C
authors.lastname: Pedrós
authors.forename: A
authors.initials: A
authors.lastname: Figueras
mesh_terms: D000978:Antiparkinson Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001577:Benzophenones / Q000009:adverse effects* / Q000627:therapeutic use; D065098:Catechol O-Methyltransferase Inhibitors; D004791:Enzyme Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D009596:Nitrophenols; D010300:Parkinson Disease / Q000188:drug therapy*; D000077867:Tolcapone; D014820:Vitiligo / Q000139:chemically induced*
chemical_list: D000978:Antiparkinson Agents; D001577:Benzophenones; D065098:Catechol O-Methyltransferase Inhibitors; D004791:Enzyme Inhibitors; D009596:Nitrophenols; D007980:Levodopa; D000077867:Tolcapone